VivoSeq
Other

Telangiectasis

4

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Telangiectasis is an early-stage landscape with 4 programs across 2 companies. The most active players are Roche, Regeneron. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Anecortave Acetate

Alcon Research

Ranibizumab

Roche

Phase 32

Bevacizumab

Bio-Thera Solutions

Aflibercept

Regeneron

Approved
No programs

Analysis

Modality Breakdown

4programs
Monoclonal antibody250%
Small molecule125%
Protein / enzyme125%

Modality classified for 100% of 4 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)